Harmony Management Patent-Cliff Exposure & CMS Drug Spending Portfolio
Harmony Management (US): 1 reconciled FDA prescription therapies (100.0% 2025 to 2030 cliff risk), $250.5M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | US |
| Reconciled FDA Portfolio Therapies | 1 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 100.0% |
| Primary Portfolio LOE Date | 2033-01-01 |
| 2024 CMS Total Public Spend | $250.5M |
| 2024 Medicare Part D Spend | $132.5M |
| 2024 Medicaid Spend | $118.1M |
| California HCAI SB 17 Filings | 4 WAC filings (max 22.5% 2-yr change) |